SHS Capital
SHS Capital is an independent German private equity firm founded in 1993 that manages ~€270M healthcare-dedicated funds, investing majority and minority equity tickets of €10-50M in growth-stage medtech, pharma, and life sciences companies across DACH, Nordics, and Benelux.
- Company typePrivate
- Founded1993
- HeadquartersTübingen, Germany
- Headcount11–50
- GTM typeB2B
- OfferingServices
What SHS Capital does
SHS Capital (legally SHS Gesellschaft für Beteiligungsmanagement mbH) is an independent German private equity firm headquartered in Tübingen, founded in 1993, that exclusively invests in the European healthcare sector. The firm manages closed-end private equity funds — currently operating the sixth generation (SHS VI, approximately €270M) and launching a seventh (SHS VII) — and takes both majority and minority equity positions in growth-stage healthcare SMEs and scale-ups across the DACH region, Nordics, and Benelux. Typical equity tickets are €10-50M for companies with enterprise values up to €150M. SHS screens approximately 1,000 deal flow cases per year through an in-house Healthcare Expert Network spanning leading European scientists, clinicians, and industry specialists. Since inception the firm has completed 75 investments and 50 exits, currently holds 20+ active portfolio companies, and its portfolio companies collectively serve approximately 17 million patients across 88 countries.
The firm's underlying platform combines capital with operational support across market access, reimbursement strategy, regulatory affairs (MDR/IVDR), M&A execution, and exit planning. Proprietary infrastructure includes the SHS Healthcare Expert Network, an annual ESG scoring and quarterly monitoring system applied across pre-investment, holding, and exit phases, the SHS Academy for internal capability building, and a Portfolio Workshop Series on topics such as cybersecurity, supply chain, and Buy-and-Build strategies. The senior team comprises four Managing Partners (Sascha Alilovic, Uwe Steinbacher, Manfred Ulmer-Weber, Lukas Maucher/CFO) supported by senior and junior Partners, Investment Managers, and a dedicated ESG lead.
Revenue is generated through standard European private equity fund economics: recurring management fees on committed capital (SHS VI alone representing ~€270M in fee-earning AUM) plus performance-based carried interest on exits. Limited Partners include pension funds, fund-of-funds, foundations, family offices, strategic investors, entrepreneurs, and the SHS management team, with co-investment opportunities made available to LPs alongside main fund commitments. The firm is a UN PRI signatory, publishes SFDR disclosures, and achieved climate-neutral operations in 2024.
SHS Capital firmographics
Firmographics- Name
- SHS Capital
- Legal name
- SHS Gesellschaft für Beteiligungsmanagement mbH
- Website
- http://www.shs-capital.eu
- Company type
- Private
- Founded year
- 1993
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- SHS Capital is an independent German private equity firm founded in 1993 that manages ~€270M healthcare-dedicated funds, investing majority and minority equity tickets of €10-50M in growth-stage medtech, pharma, and life sciences companies across DACH, Nordics, and Benelux.
- Ownership category
- akta.pro rank
SHS Capital industry classification
Industry- Product category
- Healthcare Private Equity
- NAICS
- Portfolio Management and Investment Advice (523940)
- SIC
- Investment Advice (6282)
- akta.pro primary industry
- Capital Raising Advisory (Equity & Equity-Linked) (FSAEAGAC)
Keywords
Where SHS Capital is headquartered
LocationHeadquarters
- HQ city
- Tübingen
- HQ country
- Germany
- HQ region
- Europe
Offices1 record
Markets served
SHS Capital business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure
Revenue model
- Private Equity Fund Management: SHS Capital raises and manages closed-end private equity funds (currently SHS VI, targeting SHS VII), investing in healthcare companies across Europe. Revenue is generated through management fees and performance-based carried interest from institutional investors (pension funds, foundations, family offices, strategic investors, entrepreneurs, and SHS management). The fund targets companies in growth and succession situations with equity tickets of €10-50M.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | SHS VI Fund (current fund) |
Go-to-market motion1 record
Distribution channels2 records
Marketing channels6 records
SHS Capital product offering
Product offeringCore offering
SHS Capital is an independent private equity firm that raises and manages healthcare-dedicated closed-end funds (SHS VI ~€270M, SHS VII active) investing equity tickets of €10-50M (enterprise values up to €150M) in growth-stage and succession healthcare SMEs and scale-ups across the DACH region, Nordics, and Benelux. Alongside capital, the firm provides portfolio companies access to its 30-year healthcare expert network and expertise in market access, reimbursement, M&A, and exit execution.
Product overview
SHS Capital is a German private equity firm specializing in healthcare investments, operating as a fund manager rather than a product company. The firm's primary offering is the SHS VI Fund (approximately €270 million volume), which invests in European healthcare companies across the DACH region, Nordics, and Benelux. The fund focuses on growth financing, shareholder transitions, and succession situations in the healthcare sector, including medical technology, pharmaceuticals, and life sciences companies. SHS Capital provides capital along with access to their network and expertise in market access, reimbursement, marketing/sales, M&A, and exit strategies. The firm has completed over 75 investments since founding in 1993, with 50 exits, and currently manages over 20 portfolio companies.
Differentiator
Problem solved
Functional benefit
Products and services
- SHS VI Fund The sixth generation SHS private equity fund with approximately €270M volume that invests majority and minority stakes in growing European healthcare companies (MedTech, pharma, biotech, digital health) across the DACH region, Nordics, and Benelux; equity tickets typically €10-50M, target enterprise values up to €150M.
- SHS VII Fund Seventh generation healthcare-dedicated private equity fund of SHS Capital, succeeding SHS VI; invests in healthcare SMEs and scale-ups across Europe with the firm's standard majority/minority mandate.
- LP Co-Investment Opportunities Co-investment program allowing SHS limited partners to invest directly into individual portfolio companies alongside the main SHS fund vehicles.
Quantifiable outcome
- 50 exits completed since founding in 1993
- +1 more outcomes
Companies that use SHS Capital
Customer profileNamed customers1 record
Segments2 records
Ideal customer profiles2 records
SHS Capital technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
SHS Capital partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered minor and core.
- Altenried Etti & CominorSHS engaged Altenried Etti & Co, an investment banking boutique specialized in Buy-and-Build advisory services in healthcare, to support portfolio workshops and SHS Academy sessions on developing and executing Buy-and-Build strategies.
- ESSERT Robotics – Vetter PharmaminorESSERT Robotics (SHS portfolio company) and Vetter Pharma jointly won the ISPE RAYA Award for an outstanding automation project in pharmaceutical manufacturing.
- TRI Dental Implants – Patterson Dental PartnershipcoreTRI Dental Implants partnered with Patterson Dental as an authorized distribution partner for the TRI® matrix® implant system in the United States, making it the first abutment-free dental implant in the US market. Patterson Dental distributes TRI's digital dental solutions to US customers.
- Simulands – Leading US MedTech CompanyminorSimulands (SHS portfolio company, Zurich) partnered with a leading US MedTech company to equip their entire field sales team with the simuGO portable medical simulator for cardiovascular procedure demonstrations.
Scale indicators10 records
Recent moves6 records
Expansion highlights6 records
SHS Capital competitors and assessment
Company assessmentDirect peers
- Wellington Partners: Munich-based venture and growth investor focused on European technology and healthcare/life sciences companies. Comparable DACH presence and healthcare growth-stage mandate.
- Andera Partners: Paris-based private equity firm with the dedicated Andera Life Sciences franchise (formerly Edmond de Rothschild) investing in European healthcare growth companies. Comparable healthcare focus, lower mid-market ticket sizes, and minority/majority flexibility.
- ArchiMed: French healthcare-specialist private equity firm backing European medtech, pharma services, and care providers across mid-market transactions. Direct peer given healthcare-only mandate and similar growth/buyout strategy in Europe.
- GIMV: Belgian-listed investment company with a dedicated Health & Care platform investing in growth-stage European healthcare companies, with strong Benelux and DACH presence. Highly comparable to SHS given overlapping geographies, healthcare specialization, and mid-market equity ticket sizes.
- EQT Life Sciences: EQT's healthcare-dedicated growth and venture arm investing across European and US life sciences with a focus on growth-stage healthcare companies. Comparable healthcare-only mandate at a larger scale.
- Sofinnova Partners: Paris-headquartered European healthcare specialist with dedicated medtech and biotech strategies investing in growth-stage healthcare companies. Overlaps with SHS in healthcare focus and European mid-market deployment.
- Forbion: Dutch/European life sciences venture and growth capital firm investing in healthcare and biotech companies. Overlaps with SHS in healthcare specialization and Benelux/DACH/Nordic geographic coverage.
Broad incumbents
- LBO France: French private equity firm with a dedicated Healthcare strategy (e.g., LBO France Hexagone Santé) investing in European mid-market healthcare. Broader multi-strategy firm but with directly comparable healthcare PE franchise.
- Montagu: London-headquartered European mid-market private equity firm with healthcare exposure across pharma services, medical devices, and consumer health. Comparable mid-market size and European geography.
Emerging players
- Amadeus Capital Partners: European deep-tech and healthcare growth investor with activity in medtech and digital health. Comparable in European mid-market deal sizes but with broader tech focus rather than healthcare-only mandate.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
SHS Capital social profiles
Digital presenceSHS Capital compliance and trust
Trust signalCompliance3 records
SHS Capital financial estimates
Financial estimateRevenue estimate
Valuation estimate
SHS Capital leadership team
Management profileNumber of profiles
Profiles17 records
SHS Capital funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
SHS Capital M&A and investment
M&A and investmentM&A11 records
Investments40 records
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about SHS Capital
What does SHS Capital do?
SHS Capital is an independent private equity firm that raises and manages healthcare-dedicated closed-end funds (SHS VI ~€270M, SHS VII active) investing equity tickets of €10-50M (enterprise values up to €150M) in growth-stage and succession healthcare SMEs and scale-ups across the DACH region, Nordics, and Benelux. Alongside capital, the firm provides portfolio companies access to its 30-year healthcare expert network and expertise in market access, reimbursement, M&A, and exit execution.
Is SHS Capital a public or private company?
SHS Capital is a private company. It is classified as management employee owned and is currently operating.
When was SHS Capital founded?
SHS Capital was founded in 1993. It employs 11 to 50 people.
Where is SHS Capital based?
SHS Capital is headquartered in Tübingen, Germany, in the Europe region.
How does SHS Capital make money?
One revenue line is on record: private Equity Fund Management.
Who are SHS Capital's main competitors?
Direct peers on record are Wellington Partners, Andera Partners, ArchiMed, GIMV, EQT Life Sciences, Sofinnova Partners and Forbion. Broad incumbents are LBO France and Montagu. Amadeus Capital Partners is listed as an emerging player.
Does SHS Capital have an API?
No public API is recorded for SHS Capital.
What industry is SHS Capital in?
SHS Capital's product category is Healthcare Private Equity. Its primary akta.pro industry code is FSAEAGAC, Capital Raising Advisory (Equity & Equity-Linked). Its NAICS code is 523940 and its SIC code is 6282.